Cardiome Announces its Presence at the ESC Congress 2013 in Amsterdam

    Cardiome Announces its Presence at the ESC Congress 2013 in Amsterdam

  PR Newswire

  VANCOUVER, August 29, 2013

VANCOUVER, August 29, 2013 /PRNewswire/ --



NASDAQ: CRME  TSX: COM

Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that the
company will host an exhibit booth and has sponsored a satellite symposium at
the upcoming ESC Congress 2013 held in Amsterdam, The Netherlands from August
31 ^st to September 4 ^th . This annual conference is organised by the
European Society of Cardiology and focuses on the science, management and
prevention of cardiovascular disease.

"We are excited to be able to participate again at the prestigious European
Society of Cardiology Annual Congress Meeting," said Karim Lalji, Cardiome's
Chief Commercial Officer. "This marks the first of several important upcoming
meetings in Europe in which Cardiome plans to actively participate as we
continue to execute our commercialization strategy for BRINAVESS."

The satellite symposium, titled "Recent Advances in the Management of Atrial
Fibrillation" will be held on Saturday, August 31 ^st from 13:00 to 14:00 in
the Skopje Room at the Amsterdam RAI Exhibition and Convention Center. The
symposium program is as follows:

         Chairmen: H. Crijns (Maastrict, NL) and J.L. Merino (Madrid, ES)

    13:05 - 13:20: D. Atar (Oslo, NO); The 2012 ESC guidelines for atrial fibrillation

    13:20 - 13:35: P. Kirchhof (Birmingham, UK); Economic aspects of atrial fibrillation
    13:35 - 13:50: J. Hartikainen (Kuopio, FI); Real-life experience with vernakalant:
                   Who is the right patient for this drug?
    13:50 - 14:00: Conclusion and closing remarks

A webcast of the symposium will be made available to the public at the ESC
Congress 365 website ( http://congress365.escardio.org/home.aspx ) until
September 2014.

About Cardiome Pharma Corp. Cardiome Pharma Corp. is a biopharmaceutical
company dedicated to the discovery, development and commercialization of new
therapies that will improve the health of patients around the world. Cardiome
has one marketed product, BRINAVESS ^[ ^TM ^] (vernakalant IV), approved in
Europe and other territories for the rapid conversion of recent onset atrial
fibrillation to sinus rhythm in adults.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock
Exchange (COM). For more information, please visit our website at
http://www.cardiome.com .

Forward-Looking Statement Disclaimer Certain statements in this news release
contain forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 or forward-looking information under
applicable Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate", "intend",
"expect" and similar expressions. Forward- looking statements may involve,
but are not limited to, comments with respect to our objectives and priorities
for the remainder of 2013 and beyond, our strategies or future actions, our
targets, expectations for our financial condition and the results of, or
outlook for, our operations, research and development and product and drug
development. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Many
such known risks, uncertainties and other factors are taken into account as
part of our assumptions underlying these forward-looking statements and
include, among others, the following: general economic and business conditions
in the United States, Canada, Europe, and the other regions in which we
operate; market demand; technological changes that could impact our existing
products or our ability to develop and commercialize future products;
competition; existing governmental legislation and regulations and changes in,
or the failure to comply with, governmental legislation and regulations;
availability of financial reimbursement coverage from governmental and
third-party payers for products and related treatments; adverse results or
unexpected delays in pre-clinical and clinical product development processes;
adverse findings related to the safety and/or efficacy of our products or
products; decisions, and the timing of decisions, made by health regulatory
agencies regarding approval of our technology and products; the requirement
for substantial funding to expand commercialization activities; and any other
factors that may affect our performance. In addition, our business is subject
to certain operating risks that may cause any results expressed or implied by
the forward-looking statements in this presentation to differ materially from
our actual results. These operating risks include: our ability to attract and
retain qualified personnel; our ability to successfully complete pre-clinical
and clinical development of our products; changes in our business strategy or
development plans; intellectual property matters, including the
unenforceability or loss of patent protection resulting from third-party
challenges to our patents; market acceptance of our technology and products;
our ability to successfully manufacture, market and sell our products; the
availability of capital to finance our activities; and any other factors
described in detail in our filings with the Securities and Exchange Commission
available at http://www.sec.gov and the Canadian securities regulatory
authorities at http://www.sedar.com . Given these risks, uncertainties and
factors, you are cautioned not to place undue reliance on such forward-looking
statements and information, which are qualified in their entirety by this
cautionary statement. All forward-looking statements and information made
herein are based on our current expectations and we undertake no obligation to
revise or update such forward-looking statements and information to reflect
subsequent events or circumstances, except as required by law.

SOURCE: Cardiome Pharma Corp.

For further information:

Cardiome Investor Relations +1-(604)-676-6993 or Toll Free: 1-800-330-9928
Email: ir@cardiome.com